A1SLIDES · THE DOSE
The Orphan Premium
Four policy levers, one direction, and the conditions attached to each.
Issue 005 · October 2026
Data cut-off: 7 October 2026
In This Issue
Policy levers rarely line up. This autumn, four did. In the seven weeks since 19 August the FDA awarded four rare pediatric disease vouchers and its drug center cleared 22 novel drugs in a single quarter. A 100% tariff on patented medicines reached every remaining manufacturer on 29 September, with a conditional carve-out for orphan-only drugs. On 7 October, Ultragenyx announced the sale of one voucher for $210 million. The premium on rare disease is real. It also comes with conditions, and this issue is about who can take it back.
TL;DR
Rare disease now has four tailwinds, held by four different institutions. FDA: CDER approved 45 novel drugs through 28 September (46 in all of 2025), 22 of them in Q3; seven rare-disease products won approval in under six weeks across CDER and CBER. Vouchers: four awarded in 30 days; 2026 sales have ranged $180M–$210M. Tariffs: the 100% Section 232 duty reached all remaining companies on 29 September; orphan-only drugs get a zero rate if made in one of 19 listed jurisdictions. Medicare: drugs approved only for orphan indications leave price negotiation from the 2028 cycle, which closes talks on 1 November.
Elsewhere: the EU Council adopted the pharma package (28 September); six China-originated licences carried about $1.06bn upfront in September; Q3 M&A cooled from Q2’s roughly $77bn but stayed healthy; the FDA is still led by an acting commissioner.
Executive Summary
Four tailwinds, four owners, conditions on each. CDER cleared 22 novel drugs in Q3 against 10 in Q1, and the rare-disease run spanned both CDER and CBER. Fayuvi won standard full approval on 17 treated children against 27 external controls. Voucher prices held at $180M–$210M despite more supply. The tariff’s zero rate for orphan-only drugs depends on where the drug is made, and Medicare’s exclusion ends at a first non-orphan approval. Each lever belongs to a different institution, and the FDA’s is run by an acting commissioner.
Capital is buying capacity, and licensing from China at scale. Q3 M&A cooled from Q2’s roughly $77bn but stayed healthy. Four of the seven Q3 deals on our board (Integer, PolyPeptide, ITM, ArisGlobal) buy manufacturing capacity, isotope supply or regulated-process software as much as pipeline. In September six China-originated licences carried about $1.06bn upfront against headline values as much as 33 times larger.
The rulebook is being rewritten in several places at once. The EU Council adopted its pharma package on 28 September, with Parliament still to vote. Medicare’s third negotiation cycle closes on 1 November. The FDA’s commissioner nominee was heard on 24 September. The UAE approved a new drug 33 days after the FDA. Dates move. Assumptions need owners.
An incentive is not evidence. The decks that survive this autumn’s tailwinds will put the comparator, the confirmation plan and the policy dependency on the same slide.
The Dose · Issue 005
Get the next issue before your next pitch.
Funding signals, regulatory moves and presentation insights for life sciences teams, once a month.
One email a month. Unsubscribe anytime.
01 · The Signal
One structural shift. Explained clearly.
Rare disease has long carried a policy premium: orphan exclusivity, fee waivers, tax credits. What changed this autumn is that four newer levers, held by four different institutions, moved the same way within weeks of each other.
Lever 1 · The FDA is approving more, and often early
CDER cleared 22 novel drugs in the third quarter, against 10 in Q1 and 13 in Q2 (Figure 1). Through 28 September the year’s count stood at 45, one short of all of 2025. Rare disease drove the late-summer run, across both regulators: five CDER approvals (Pasatru on 19 August, then Zanvastro, Isembyld, Atebrioz and Emcitate) and two CBER gene therapies (Genglycos on 19 August and Fayuvi on 17 September), seven in under six weeks. The evidence behind them is worth reading closely. Fayuvi received standard full approval on a comparison of 17 treated children with 27 untreated patients from an external natural-history cohort; the company reports a 23.5-point advantage on the Bayley-III cognitive score (p<0.0001). Genglycos was approved on a surrogate, reduced daily cornstarch intake, from a 46-participant randomised trial, with a two-year commitment to follow 50 treated patients and 20 controls.
Figure 1 · FDA novel drug approvals (CDER)
Annual totals and the 2026 quarterly breakdown
Number of approvals · Zero-based scale
Scroll horizontally where needed to compare all values.
Annual approvals
2026 by quarter
2026 annual total through 28 September. Annual and quarterly panels use separate zero-based scales. CDER only; CBER gene therapies are excluded.
Source: FDA, Novel Drug Approvals lists for 2023–2026 (2026 current to 28 Sep 2026); quarterly counts are A1 tallies of the FDA table. Fayuvi and Genglycos are CBER products and are not in these counts.
Lever 2 · The voucher: more supply, no discount
Genglycos, Zanvastro, Isembyld and Fayuvi each carried a rare pediatric disease priority review voucher: four in 30 days. Prices did not fall. Disclosed 2026 sales ran from $180 million to $210 million: Jazz $200M (January), Fortress $205M (February), Rocket $180M (April), Denali $195M (June) and Ultragenyx $210M, announced on 7 October under an agreement dated 6 October (Figure 2). That is 13–40% above the $150–160 million paid in 2025, but not a straight line: Rocket’s $180M was a dip, and the Ultragenyx sale remains subject to antitrust clearance. The program is authorised through September 2029. Redeeming a voucher costs a $1.80 million fee in FY2027 (FY2026: $1.96 million) on top of the $4.60 million application fee for a filing with clinical data. At $180–210 million each, the four vouchers are worth $720–840 million on paper, although only one has traded.
Figure 2 · Disclosed voucher sale prices, August 2024 to October 2026
August 2024 — October 2026
US$ millions · Zero-based scale
Scroll horizontally where needed to compare all values.
Disclosed sales in chronological order, equally spaced by transaction. Some 2025 dates are approximate. Ultragenyx’s October 2026 sale is subject to antitrust clearance. The historical disclosed high was $350M in 2015, outside this period.
Source: company announcements, SEC filings and trade press (Ipsen, PTC, Acadia, Zevra, Abeona, Bavarian Nordic, Jazz, Fortress/Cyprium, Rocket, Denali, Ultragenyx). The list covers disclosed sales we found and may be incomplete; several 2025 dates are approximate.
Lever 3 · The tariff: a conditional carve-out
On 29 September the 100% Section 232 duty on patented drugs and ingredients began to apply to every importer not already covered since 31 July. Commerce’s 21 September guidance sets a zero rate for “specialty” products: drugs whose every approved indication is orphan, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates and CBRN countermeasures. The zero rate applies only if the product comes from one of 19 listed jurisdictions, or if Commerce finds an urgent US health need case by case. The list includes the EU, UK, Switzerland, Japan, South Korea and India; China is not on it. US-made products sit outside the tariff altogether, as Fayuvi and Genglycos do (Table 1).
Table 1 · Section 232 duty tiers on patented pharmaceuticals
| Category | Duty |
|---|---|
| Patented drugs and APIs (default) | 100% |
| Products of the EU, Japan, South Korea and Switzerland | 15% |
| Company has a Commerce-approved onshoring plan | 20% |
| Onshoring plan plus an HHS most-favoured-nation pricing agreement | 0% until 20 Jan 2029 |
| Orphan-only drugs and other specialty products, if from a listed jurisdiction or approved as urgent need | 0% |
| Clinical-trial, R&D and other non-commercial imports (new heading 9903.04.70) | 0% |
| Generics, biosimilars and US-made products | Exempt |
Source: Federal Register notices 2026-19498 (23 Sep 2026) and 2026-09489 (13 May 2026); Crowell & Moring client alert (7 Apr 2026) for the 15% and US-origin tiers. Seventeen named companies paid the duty from 31 July; everyone else from 29 September. UK products are treated separately under the US–UK pharmaceutical agreement, and the UK is on the 19-jurisdiction list.
Lever 4 · Medicare: the orphan exclusion widened
A provision of the July 2025 reconciliation law (the ORPHAN Cures Act language) widened the orphan exclusion. From the 2028 cycle, a drug designated for one or more rare diseases and approved only for orphan indications is excluded from Medicare price negotiation, and its eligibility clock starts at its first non-orphan approval. CBO’s current estimate of the cost is $8.8 billion over 2025–2034, up from $4.9 billion in its July 2025 score once it counted Keytruda, Opdivo and Darzalex. The first cycle to which the exclusion applies closes negotiations on 1 November.
Who can take it back
Table 2 · Four levers, four owners
| Lever | What rare disease gets | Who can undo it, and on what condition | Horizon |
|---|---|---|---|
| FDA flexibility | 22 CDER approvals in Q3; full approval on an external control | Agency leadership: acting commissioner since May; nominee heard 24 Sep; Makary-era reforms were largely informal | Months |
| Priority voucher | $180–210M per voucher sold in 2026 | Congress: program authorised to September 2029 | ~3 years |
| Section 232 carve-out | Zero rate for orphan-only drugs | Commerce can change the 19-jurisdiction list; every approved indication must stay orphan; generics review due within a year | Open-ended |
| Medicare exclusion | Orphan-only drugs outside negotiation from 2028 | Congress: critics want repeal (CBO: $8.8bn); ends at a first non-orphan approval | Statutory |
Source: FDA; Ultragenyx; Skadden (June 2026); Federal Register; CBO publication 61818; Jones Day; Health Affairs Forefront.
Where the premium can leak.
Staying orphan. The tariff carve-out needs every approved indication to be orphan, and the Medicare exclusion lasts only until a first non-orphan approval. A second, non-orphan indication switches off both.
Manufacturing, not efficacy. Scholar Rock and Ultragenyx were both turned down in 2025 over manufacturing issues, and both won approval this September after resubmitting. Where a drug is made now also decides its tariff tier.
Price. Isembyld lists at about $310,000 a year and Genglycos at $2.7 million. Payers can see the same incentive stack the sponsor can.
Evidence. External controls and surrogates suit the FDA’s current posture. They are also the first things HTA bodies challenge, the pattern behind the seven comparator questions in Issue 003.
02 · Capital & Deal Pulse
Notable market movements, July to early October
Q3 cooled from Q2’s roughly $77bn of biopharma buyouts but stayed healthy. The deals below are those we verified against company filings or trade press; the list is a selection, not a league table (Table 3).
Table 3 · The Q3 deal board
| Deal | Value | Announced | What it buys |
|---|---|---|---|
| Curium – Lantheus | up to ~$8bn | 3 Aug | Radiopharmaceutical scale |
| KKR – Integer | $5.7bn EV | 3 Aug | Medical-device CDMO |
| Lilly – AtaiBeckley | up to $3.8bn | 16 Jul | Phase 3 neuroplastogen for depression |
| Lilly – Merida Biosciences | up to $2.875bn | 31 Aug | Autoantibody degraders; Lilly’s 13th deal of 2026 |
| Telix – ITM | up to $2.35bn | 21 Sep | Isotope supply and radioligand therapy |
| Dassault Systèmes – ArisGlobal | up to $2.0bn | 23 Jul | Regulatory, safety and medical-affairs software |
| Samsung Biologics – PolyPeptide | ~$1.8bn | Aug (tender) | Peptide CDMO |
Source: Scrip (5 Oct 2026); company filings and releases (Integer 8-K; Lilly; Dassault Systèmes); Labiotech (7 Oct 2026); Biobucks tracker. Lilly–Merida tender offer expires 12 October.
Read-through (our reading, not the buyers’). Four of the seven (Integer, PolyPeptide, ITM, ArisGlobal) buy manufacturing capacity, isotope supply or regulated-process software as much as pipeline. That is consistent with a market pricing in tariffs and tight capacity. One quarter cannot prove it.
Licensing ran through China again. In September, Novo, Merck, Lilly, GSK, Roche and Menarini signed six China-originated deals with a combined $1.06bn in disclosed upfront payments (Figure 3). IQVIA puts H1 2026 therapeutic in-licensing involving Chinese-originated assets at $92 billion, already 88% of the 2025 total. The BIOSECURE Act, law since 18 December 2025, restricts federal contracting with designated “biotechnology companies of concern”. Law-firm summaries read it as leaving private licensing untouched, and the deal flow agrees.
Figure 3 · China-originated licensing deals, September 2026
September 2026 · Headline values and upfront payments
US$ billions · Zero-based scale
Scroll horizontally where needed to compare all values.
Both series use the same scale. Upfront labels are in US$ millions; headline labels are in US$ billions. Headline values are potential totals, not payments made. Percentages are rounded; milestone terms differ by agreement.
Source: Labiotech (7 Oct 2026); company releases. Headline values as reported; whether “up to” totals include the upfront differs by release. Merck–SciBrunch headline is $400M upfront plus up to $2.13bn in milestones. Menarini’s €62M upfront converted at the report’s rate.
Worth sitting with. The headline is a ceiling. Across these six deals the upfront is between 3% and 16% of the “up to” figure. A slide that quotes the headline is quoting what could be paid, not what has been. For teams preparing materials for the next licensing round, see our guide to Biotech Investor Deck Design.
03 · Pipeline Watch
Regulatory and evidence signals
Table 4 · September at the FDA
| Date | Product | Indication | Why it matters |
|---|---|---|---|
| 3 Sep | Zanvastro (Ionis) | Alexander disease | First disease-modifying treatment; voucher awarded |
| 4 Sep | Etcamah (AstraZeneca) | ESR1-mutated breast cancer | Accelerated approval after ODAC voted 6–3 against (Issue 004). Boxed warning: arrhythmia risk with QTc-prolonging drugs, including ribociclib |
| 11 Sep | Isembyld (Scholar Rock) | Spinal muscular atrophy | First muscle-targeted add-on; about $310,000 a year; 19 days before its goal date |
| 17 Sep | Fayuvi (Ultragenyx) | Sanfilippo syndrome type A | First treatment; full approval on 17 vs 27 external controls; CBER. Warnings include hepatotoxicity, thrombocytopenia, TMA and malignancy risk |
| 23 Sep | Lyrfigtu (lirafugratinib) | FGFR2-rearranged cholangiocarcinoma | Previously treated, unresectable or metastatic disease |
| 25 Sep | Atebrioz (zilurgisertib) | Fibrodysplasia ossificans progressiva | Second FOP approval in five weeks, after Pasatru (19 Aug) |
| 28 Sep | Emcitate (tiratricol) | MCT8 deficiency | Rare thyroid-hormone transport disorder |
| 30 Sep | Camzyos (BMS), new label | Adolescent obstructive HCM | First disease-targeted therapy for adolescents (≥30 kg). Boxed warning: heart failure; available only through the Camzyos REMS Program |
Source: FDA Novel Drug Approvals 2026 (to 28 Sep); FDA announcement for Etcamah; company releases; Pharmacy Times (1 Oct 2026). CDER approved nine novel drugs in September; Fayuvi (CBER) and the Camzyos label extension sit outside that count. Boxed-warning status is shown only where we checked the label or FDA announcement (Etcamah, Camzyos); check the other labels before relying on this table.
Scorecard: what Issue 004 said would happen
| Item | Issue 004 listed | Outcome |
|---|---|---|
| Zilurgisertib | Goal date 26 Sep | Approved 25 Sep (Atebrioz) |
| Apitegromab | Goal date 30 Sep | Approved 11 Sep (Isembyld), 19 days early |
| UX111 | Goal date 19 Sep | Approved 17 Sep (Fayuvi), standard full approval |
| Mavacamten, adolescents | Goal date 30 Sep | Approved 30 Sep |
| Lilly – Merida tender | 15 Sep – 12 Oct | Open as of 7 Oct; expires 12 Oct |
| Zidesamtinib | “Goal date 18 Sep”, attributed to Nuvectis | Correction: our calendar entry was wrong. It was approved on 22 Jul as Jideytro; GSK completed its $10.6bn purchase of Nuvalent on 15 Jul |
Four of the five FDA decisions we listed came on or before their goal dates; the fifth was our error. With the eight approvals and label changes in Table 4, field teams face a round of material updates for each; see our guide to Medical Affairs Presentation Design.
Policy Radar
| Item | Status at 7 October | Next date | What to do |
|---|---|---|---|
| EU pharma package | Council adopted 28 Sep; Parliament vote and Official Journal publication to follow; transition to about 2028 | Parliament vote to be scheduled | Rebuild exclusivity curves on 8 years of data protection plus 1 of market protection, with extensions capped at 11 years. |
| UK | NICE threshold £25–35k per QALY in effect since April (NICE expects 3–5 extra positive recommendations a year); newer-medicine rebate 14.5% for 2026, capped at 15% to 2028 | n/a | Re-run shelved NHS cost-effectiveness cases (see Issue 004). |
| UAE | Emirates Drug Establishment approved rusfertide (Mimrylo) on 30 Sep, 33 days after the FDA | n/a | Test Gulf launch sequencing against reliance-pathway timelines. |
| BIOSECURE | Law since 18 Dec 2025: federal-contracting limits on designated “biotechnology companies of concern” | Agency implementation ongoing | Add manufacturing and data-supplier checks to China-sourced asset diligence. |
Source: Council of the EU via Matheson (30 Sep 2026); House of Commons Library; GOV.UK; Emirates Drug Establishment (30 Sep 2026); MoFo. For teams rebuilding cost-effectiveness cases under the new NICE threshold, see our guide to HEOR Presentation Design.
On the calendar
Regulatory decisions, deal deadlines and policy milestones.
As of 7 October
October 2026
- OctFDA goal date
Tecentriq (atezolizumab)
Stage III colon cancer.
- OctGoal date
Ifinatamab deruxtecan
Merck and Daiichi Sankyo · Extensive-stage small cell lung cancer.
- OctDeal deadline
Lilly–Merida
Tender offer expires.
- OctGoal date
Enspryng (satralizumab)
Thyroid eye disease.
- OctCongress
ESMO Congress
Madrid.
- OctGoal date
Bepirovirsen
GSK · Chronic hepatitis B.
- OctGoal date
INO-3107
Inovio · Recurrent respiratory papillomatosis; accelerated-approval BLA.
November 2026
- NovPolicy deadline
Medicare negotiation
Negotiation period ends for the 2028 cycle.
- NovExtended goal date
Deramiocel
Capricor.
- NovPolicy milestone
CMS negotiated prices
CMS publishes negotiated prices.
Dates as of 7 October. Goal dates come from sponsor disclosures and trade calendars; confirm against company announcements before relying on them.
04 · The Deck
How clinical data actually gets read
Standard 04 asked every deck to show both halves of an accelerated approval. Standard 05 goes one layer down, to the comparator.
Standard 05: The comparator is part of the claim.
Fayuvi’s full approval rests on 17 treated children and 27 untreated patients from an external natural-history cohort. Regulators can accept that comparison. Payers and HTA bodies will ask about the 27. A slide that shows only the treated group’s improvement shows half of the claim, and invites the question in a room where you cannot answer it.
Put the comparator’s n beside the treated n, on the chart. “n=17 vs n=27” belongs in the title or legend, not the footnote.
Say where the comparator came from (concurrent, historical, natural-history cohort, external control) and how it was matched.
Name the surrogate and what it is expected to predict. “Reduced cornstarch intake” and “walking speed” are endpoints with a story attached. Show the story.
Give the confirmation plan its own line: study, population, timing. Genglycos: 50 treated patients and 20 controls over two years.
For the chart mechanics behind this standard, see our Clinical Data Visualization Playbook and the new Life Sciences Presentation Report 2026 (see Off The Deck).
06 · Off The Deck
What’s new at A1 Slides
New research report: The Life Sciences Presentation Report 2026. Subtitled The Perception Science Behind Clinical Data Communication, the report brings together peer-reviewed research and industry benchmarks and turns them into a seven-point standard for clinical data slides, with an editor’s view from Vaidehi Shukla. Three of its findings:
About 2×. Position on a common scale is judged about twice as accurately as angle, so the pie chart in a deck quietly costs precision (Cleveland & McGill, 1984).
56.2%. Baseline accuracy reading Kaplan-Meier plots among doctors and medical students, in a small study of 32 (arXiv 2511.08332). The report’s advice: rebuild KM curves, do not paste them.
12.8%. Share of biology research figures that are problematic for red-green colour-blind readers (eLife, 2024). They end up in congress decks.
The report also covers axis truncation, colour accessibility and the operational layer, including MLR review cycles and content utilisation. It is written for life science consultants, medical affairs and scientific communications teams, market access and HEOR teams, and commercial and brand leads. Get the report through a short registration form on the A1 Slides site.
07 · People Also Ask
What is the “orphan premium”?
The Dose uses the term for the combined advantage rare-disease drugs now hold in US policy: faster and more flexible FDA review, a transferable priority review voucher (2026 sales ranged $180M–$210M), a zero Section 232 tariff rate for orphan-only drugs made in listed jurisdictions, and a wider Medicare negotiation exclusion from the 2028 cycle. Two of those protections end when a drug gains a non-orphan indication.
Are orphan drugs exempt from the US pharmaceutical tariff?
Conditionally. Commerce’s 21 September guidance sets a zero rate for drugs whose every approved indication is orphan, but only for products of 19 listed jurisdictions (including the EU, UK, Switzerland, Japan, South Korea and India) or where Commerce finds an urgent US health need. US-made products, generics and biosimilars are exempt. Other patented drugs face 100%, with lower tiers for certain origins and onshoring agreements.
How much did the latest priority review voucher sell for?
Ultragenyx announced on 7 October 2026 a $210 million sale, under an agreement dated 6 October and subject to antitrust clearance. Earlier 2026 sales were $200 million (Jazz), $205 million (Fortress), $180 million (Rocket) and $195 million (Denali). The highest disclosed price remains $350 million, in 2015.
How many new drugs has the FDA approved in 2026?
CDER had approved 45 novel drugs through 28 September 2026, compared with 46 in all of 2025. Twenty-two came in the third quarter, against 10 in Q1 and 13 in Q2. Gene therapies such as Fayuvi and Genglycos are reviewed by CBER and sit outside that count.
Does the Medicare orphan exclusion cover any drug with an orphan designation?
No. From the 2028 negotiation cycle it covers drugs designated for one or more rare diseases and approved only for orphan indications. Eligibility is counted from the first non-orphan approval. CBO estimates the provision costs $8.8 billion over 2025–2034.
What did the EU decide on the pharma package?
The Council of the EU adopted the pharma package on 28 September 2026. New medicines receive eight years of regulatory data protection plus one year of market protection, with extensions capped at 11 years in total. The European Parliament must still adopt it before publication in the Official Journal, with full application expected around 2028.
Does the BIOSECURE Act stop licensing deals with Chinese biotechs?
Not as law-firm summaries read it. The Act, signed on 18 December 2025 within the FY2026 NDAA, restricts federal contracting with designated “biotechnology companies of concern”. Licensing continued: six China-originated deals in September carried about $1.06bn upfront. Diligence now centres on manufacturing and data suppliers.
What is The Life Sciences Presentation Report 2026?
It is an A1 Slides research report, subtitled The Perception Science Behind Clinical Data Communication. It combines peer-reviewed research and industry benchmarks into a seven-point standard for clinical data slides, covering chart encoding, Kaplan-Meier curves, axis truncation, colour accessibility and MLR review cycles. It is available through a short registration form on the A1 Slides website.
Who leads the FDA now?
Kyle Diamantas has been acting commissioner since Marty Makary resigned on 12 May 2026. President Trump nominated Dr Heidi Overton on 19 August, and the Senate HELP Committee held her confirmation hearing on 24 September.
Sources & Evidence
- FDA · Novel drug approvals, 2026
- FDA · Novel drug approvals, 2025
- FDA · Fayuvi approval letter
- FDA · Genglycos approval letter
- Ultragenyx · Fayuvi approval
- Ultragenyx · Genglycos approval
- Ultragenyx · $210M voucher agreement
- Rocket · $180M voucher sale
- Denali · $195M voucher agreement
- Jazz · February 2026 SEC filing
- Fortress · Q1 2026 SEC filing
- FDA · FY2027 prescription drug fees
- Scholar Rock · Isembyld approval
- BMS · Camzyos prescribing information
- GSK · Jideytro approval announcement
- Federal Register · Specialty drug tariffs
- White House · Pharmaceutical import rules
- Skadden · FDA leadership changes
- AABB · FDA commissioner nomination
- CMS · Third negotiation cycle fact sheet
- CBO · Orphan drug exclusion estimate
- EU Council · Pharma package adoption
- Commons Library · UK–US pharma deal
- EDE · UAE regulatory news archive
- Morrison Foerster · BIOSECURE update
- Labiotech · September biotech deals
- IQVIA · 2026 biopharma M&A outlook
- Lilly · Merida acquisition announcement
- Dassault Systèmes · ArisGlobal acquisition
- IFEMA Madrid · ESMO Congress 2026
- A1 Slides · Presentation Report 2026
